Pre-Merger Reporting Risks in U.S. M&A Transactions

The U.S. Federal Trade Commission announced a settlement involving Edwards Lifesciences Corp.'s acquisition of JC Medical from Genesis MedTech Group Limited. According to the regulator, the parties completed the acquisition without complying with notification and waiting period requirements under the Hart-Scott-Rodino Act. The settlement includes $12 million in monetary penalties.

For businesses involved in U.S. acquisitions, the case highlights a specific transaction check: before closing, teams need to assess not only commercial terms and transfer documents, but also whether pre-merger notification requirements may apply.

Check transaction process before closing documents are finalized

Pre-merger notification obligations depend on the structure of the transaction, size of the parties, and other facts of the specific deal. The existence of an acquisition alone does not establish whether a filing requirement applies.

Before closing a corporate asset transfer, review:

• transaction structure and acquired rights;
• buyer and seller roles in the deal;
• internal approvals and transaction review records;
• signing and closing timeline;
• materials supporting the notification analysis.

This review helps identify where regulatory analysis connects with the transaction timetable.

Separate a specific enforcement matter from broader M&A planning

The FTC matter concerns the particular transaction and facts described by the regulator. It does not by itself establish a rule for every acquisition in the medical device sector or every similar M&A structure.

For future transactions, preserve the evidence chain: identify who assessed filing requirements, which assumptions were used, and which documents support the transaction analysis.

Where the answer depends on transaction value, ownership structure, closing timeline, or other deal-specific facts, the applicable assessment requires review of the relevant documents and procedures.